EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study

Yoshinori Kagawa iD, Chaochen Wang iD, Yongzhe Piao iD, Long Jin, Yoshinori Tanizawa iD, Zhihong Cai iD, Yu Sunakawa iD

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01063-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Yoshinori Kagawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Osaka General Medical Center, 3 Chome-1-56 Bandaihigashi, Sumiyoshi Ward, Osaka, 558-8558, Japan. yoshikagawa@gmail.com. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Fluorouracil. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Oxaliplatin-containing adjuvant regimens (folinic acid, fluorouracil, and oxaliplatin/capecitabine and oxaliplatin [FOLFOX/CAPOX]) are used after curative resection of colorectal cancer (CRC). However, real-world evidence regarding treatment sequences and outcomes in patients with early recurrence CRC after adjuvant chemotherapy is limited. OBJECTIVE: We aimed to describe the patient characteristics, treatment sequence, and overall duration of second-line (2L) therapy in patients with early recurrence CRC who received adjuvant chemotherapy (FOLFOX/CAPOX) followed by folinic acid, fluorouracil, and irinotecan (FOLFIRI) + anti-angiogenesis drugs (AA) or FOLFIRI + anti-epidermal growth factor receptor (EGFR) antibodies. METHODS: This retrospective study analyzed Japanese administrative data from November 2014 to March 2023 of adult patients who underwent CRC resection surgery, started FOLFOX/CAPOX ≤3 months (mo) after surgery, and had early CRC recurrence. Early recurrence was defined as initiation of FOLFIRI+AA or FOLFIRI+anti-EGFR antibodies as 2L therapy, ≤12 mo of discontinuing adjuvant chemotherapy. Patient characteristics, treatment sequence, median time to treatment discontinuation (mTTD), i.e., duration between the start and end dates of 2L therapy (Kaplan-Meier method), and factors associated with 2L time to treatment discontinuation constituted the study outcomes (Cox regression model). Subgroup analyses were performed for timing of early CRC recurrence (≤6 mo and 6-12 mo) and tumor sidedness. RESULTS: Among the 832 selected patients (median age [minimum-maximum] 67 (24-86) years, 56.4% male), CAPOX (71.3%) was more commonly used than FOLFOX (28.7%) as adjuvant therapy. FOLFIRI+AA (72.5%) was used more commonly than FOLFIRI+anti-EGFR antibodies (27.5%) in 2L. AA and anti-EGFR antibodies groups had similar mTTD: 6.2 mo (95% confidence interval 5.8, 6.9) and 6.1 mo (95% confidence interval 5.2, 7.4). Age ≥70 years showed significant association with shorter 2L treatment duration (hazard ratio 1.2, 95% confidence interval 1.0, 1.4; p = 0.03). The AA cohort's mTTD was numerically shorter in the ≤6 mo recurrence subgroup compared with the 6-12 mo recurrence subgroup (6.1 mo vs 8.1 mo); the anti-EGFR antibodies cohort had similar mTTD (5.8 mo vs 6.2 mo). The AA and anti-EGFR antibodies cohorts also had similar mTTD in the left-sided CRC subgroup (6.5 mo vs 6.2 mo), but not in the right-sided subgroup (5.6 mo vs 3.9 mo). CONCLUSIONS: This is the first administrative data-based real-world evidence on treatment sequence and outcomes for patients with early recurrence CRC treated with FOLFIRI+AAs or FOLFIRI+ anti-EGFR antibodies after adjuvant FOLFOX/CAPOX therapy in Japan. Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsFluorouracilLeucovorinNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedCamptothecinChemotherapy, AdjuvantEast Asian PeopleErbB ReceptorsJapanOrganoplatinum CompoundsRetrospective Studies

Substanzen

Angiogenesis InhibitorsCamptothecinEGFR protein, humanErbB ReceptorsFluorouracilLeucovorinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Osaka General Medical Center, 3 Chome-1-56 Bandaihigashi, Sumiyoshi Ward, Osaka, 558-8558, Japan. yoshikagawa@gmail.com.
  • Osaka International Cancer Institute, Osaka, Japan. yoshikagawa@gmail.com.
  • Eli Lilly Japan K.K., Kobe, Japan.
  • St. Marianna University School of Medicine, Kawasaki, Japan.

ORCID-Profile: Yoshinori Kagawa, Chaochen Wang, Yongzhe Piao, Yoshinori Tanizawa, Zhihong Cai, Yu Sunakawa

Förderung

  • Eli Lilly Japan

Zitieren

APA

Kagawa, Y., Wang, C., Piao, Y., Jin, L., Tanizawa, Y., Cai, Z., & Sunakawa, Y. (2024). Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study. Targeted Oncology. https://doi.org/10.1007/s11523-024-01063-y

Vancouver

Kagawa Y, Wang C, Piao Y, Jin L, Tanizawa Y, Cai Z, et al. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study. Targeted Oncology. 2024. doi:10.1007/s11523-024-01063-y

BibTeX
@article{Kagawa2024,
  author = {Kagawa, Yoshinori and Wang, Chaochen and Piao, Yongzhe and Jin, Long and Tanizawa, Yoshinori and Cai, Zhihong and Sunakawa, Yu},
  title = {Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01063-y}
}
Kostenlos starten →